Last updated: May 4, 2026
CA2976106 (Canada) Drug Patent: Scope, Claims, and Patent Landscape
What is CA2976106, and what does it cover?
CA2976106 is a Canadian patent publication in the “drug patents” space tied to a defined therapeutic product profile, with enforceable subject matter defined by its independent and dependent claims (composition, formulation, and/or method-of-use patterns are typical for Canadian drug filings).
However, a complete and accurate scope-and-claims analysis requires the actual text of CA2976106 (claim set, dependent claim architecture, claim numbering, and full description linkages), plus confirmation of the Canadian filing family’s priority and any related US/EP applications. Those core claim artifacts are not available in the current context, so a complete, evidence-backed analysis cannot be produced.
What are the independent claim boundaries in CA2976106?
A claim boundary analysis must extract, for each independent claim:
- the exact product definition (chemical entity, salt, polymorph, hydrate, stereochemistry, or regimen)
- the exact formulation definition (excipients, concentration ranges, dosage unit design)
- the exact method-of-use boundary (patient population, indication, dosing schedule, route)
- any explicit exclusions, limitations, or “wherein” structures that narrow scope
These elements require verbatim access to CA2976106 claim text. Without it, any listing of independent claim boundaries would be speculative.
How do dependent claims narrow or expand the scope?
A dependent-claim landscape maps:
- which dependent claims are anchored to which independent claim
- whether narrowing features are structural (salt, polymorph, hydrate, stereoisomer), compositional (carrier, excipient, concentration), or procedural (dosing schedule, patient selection)
- whether there are multiple “alternative” embodiments that broaden coverage (coexisting subranges, alternative salts, alternative dosing windows)
This requires the full dependent claim set and dependency graph. That claim data is not available here.
What is the patent landscape around CA2976106 in Canada?
A reliable landscape must identify, at minimum:
- related family members in Canada (continuations/divisionals or sibling applications if present)
- related patents in the same therapeutic class that could create layered blocking (process, formulation, combination, polymorph/patentable forms)
- regulatory linkage context in Canada (whether the patent maps to a specific drug product for a given strength and dosage form) and whether it appears in the Patented Medicines (Notice of Compliance) framework
A landscape also needs:
- the patent’s assignee/owner and publication family to determine co-owned or cross-licensed boundaries
- the expiry and any patent term adjustments (including supplementary protection where applicable)
- any litigation or claim construction outcomes that narrow enforceable scope
None of those inputs can be derived from the current context.
Scope summary that can be stated from available information
No scope statements, claim groupings, or landscape assertions about CA2976106 can be made without the patent text and bibliographic records that enumerate:
- the claim list and the exact wording
- the assignee/owner
- the priority filing dates and family members
- the CPC/IPC classification and legal status events
To avoid inventing or guessing claim content, this response contains no claim mapping.
Key Takeaways
- CA2976106 scope and claims cannot be analyzed to a litigation-grade standard without access to the patent’s claim text and bibliographic records.
- No evidence-backed Canada patent landscape in the PM(NOC) context can be produced without the publication family, assignee, and related Canadian patent set.
FAQs
-
Can you list the independent claims of CA2976106 and summarize each limitation?
Not from the current context; the claim text is required to provide a precise, non-speculative summary.
-
Which dependent claims narrow CA2976106 (salt, polymorph, formulation, dosing)?
Not from the current context; dependent claim wording and dependency structure are required.
-
What other Canadian patents are likely layered around CA2976106 (same family or same product)?
Not from the current context; bibliographic and family data are required to identify related filings.
-
Does CA2976106 tie into PM(NOC) listings for a specific DIN/strength/form?
Not from the current context; regulatory linkage data is required.
-
What is the likely expiry timeline and effect of term adjustments for CA2976106?
Not from the current context; priority dates and legal status events are required.
References
[1] Not available in the provided context.
